ClinMed Pharma is a Polish research organisation that provides services to biotech and pharmaceutical companies in all phases of clinical trials. The organisation designs and conducts research on behalf of the funding organization throughout Europe.
In 2017 Max Biocare funded ClinMed Pharma to run a clinical trial on Tregocel®. To find out more information, please the Research and Innovation Platform at the MBCI
Max Biocare & ClinMed Pharma
Trial topic
Joint aches and pains.
Trial center
ClinMed Pharma, Poland.
Objective
To assess efficacy of Tregocel® in addition to standard of care treatment in patients with symptomatic joint aches and pains.
Sample
Individuals aged ≥40 years with joint aches and pains.
Methods
A total of 150 participants have been recruited and assigned Tregocel® (2/day) orally for 36 weeks. Efficacy will be assessed by changes in ambulatory mobility as well as perceived pain, stiffness and difficulty with daily tasks. Safety will be assessed by concurrent monitoring of hematological and urine parameters.
Results
This study is currently in progress and is registered with the U.S National Library of Medicine, click here for details.
Contact Details
